Targeting GPCR signaling in HER2+breast cancer suppresses cancer stem cell tumorigenicity and sensitizes HER2-targeted therapies

被引：0
|
作者：
Wang, Wei [1 ]
Bhargava, Dharmendra [1 ]
Ye, Yuan Chao [1 ]
Chen, Songhai [1 ]
机构：
[1] Univ Iowa, Iowa City, IA USA
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2019-4683
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4683
引用
收藏
页数：2
相关论文
共 50 条
  • [31] HER2-targeted therapies for HER2-positive early-stage breast cancer: present and future
    Xu, Luying
    Xie, Yuxin
    Gou, Qiheng
    Cai, Rui
    Bao, Rong
    Huang, Yucheng
    Tang, Ruisi
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [32] Alterations in immune cell phenotype and cytotoxic capacity in HER2+breast cancer patients receiving HER2-targeted neo-adjuvant therapy
    Gaynor, Nicola
    Blanco, Alfonso
    Madden, Stephen F.
    Moran, Barry
    Fletcher, Jean M.
    Kaukonen, Damien
    Ramirez, Javier Sanchez
    Eustace, Alex J.
    McDermott, Martina S. J.
    Canonici, Alexandra
    Toomey, Sinead
    Teiserskiene, Ausra
    Hennessy, Bryan T.
    O'Donovan, Norma
    Crown, John
    Collins, Denis M.
    BRITISH JOURNAL OF CANCER, 2023, 129 (06) : 1022 - 1031
  • [33] Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+breast cancer
    Gagliato, Debora de Melo
    Fontes Jardim, Denis Leonardo
    Pereira Marchesi, Mario Sergio
    Hortobagyi, Gabriel N.
    ONCOTARGET, 2016, 7 (39) : 64431 - 64446
  • [34] Cardiotoxicity of HER2-targeted therapies
    Copeland-Halperin, Robert S.
    Liu, Jennifer E.
    Yu, Anthony F.
    CURRENT OPINION IN CARDIOLOGY, 2019, 34 (04) : 451 - 458
  • [35] AKT3 activation mediates resistance to HER2-targeted therapies in HER2-amplified breast cancer
    Sanz, F. Carmona
    Montemurro, F.
    Rossi, V.
    Verma, C.
    Berger, M.
    Baselga, J.
    Scaltriti, M.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 27 - 28
  • [36] The role of HER2 alterations in clinicopathological and molecular characteristics of breast cancer and HER2-targeted therapies: a comprehensive review
    Asgari-Karchekani, Shafighe
    Aryannejad, Armin
    Mousavi, Seied Asadollah
    Shahsavarhaghighi, Shirin
    Tavangar, Seyed Mohammad
    MEDICAL ONCOLOGY, 2022, 39 (12)
  • [37] The role of HER2 alterations in clinicopathological and molecular characteristics of breast cancer and HER2-targeted therapies: a comprehensive review
    Shafighe Asgari-Karchekani
    Armin Aryannejad
    Seied Asadollah Mousavi
    Shirin Shahsavarhaghighi
    Seyed Mohammad Tavangar
    Medical Oncology, 39
  • [38] A systematic review and meta-analysis of intrathecal versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+breast cancer leptomeningeal metastases
    Lazaratos, Anna-Maria
    Maritan, Sarah M.
    Darlix, Amelie
    Ratosa, Ivica
    Ferraro, Emanuela
    Griguolo, Gaia
    Pellerino, Alessia
    Hofer, Silvia
    Jacot, William
    Stemmler, Hans-Joachim
    van den Broek, Marcel
    Panet, Francois
    Lahijanian, Zubin
    Morikawa, Aki
    Seidman, Andrew David
    Soffietti, Riccardo
    Petrecca, Kevin
    Bouganim, Nathaniel
    Dankner, Matthew
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [39] Targeting glucose metabolism in HER2+breast cancer.
    Chang, Simone
    Chesney, Jason
    Trent, John O.
    Telang, Sucheta
    CANCER RESEARCH, 2021, 81 (13)
  • [40] Targeting HER2+Breast Cancer Brain Metastases: A Review of Brain-Directed HER2-Directed Therapies
    Chiec, Lauren
    Kumthekar, Priya
    CNS DRUGS, 2022, 36 (02) : 167 - 179
12345